Kawasaki Disease Conjunctivitis

What is Kawasaki disease conjunctivitis?

Kawasaki disease (KD) is an acute, self‑limited vasculitis that primarily affects children under five years of age. One of the hallmark features of KD is a bilateral, non‑purulent conjunctival injection – commonly called “Kawasaki disease conjunctivitis.” The redness involves the bulbar conjunctiva of both eyes, sparing the eyelids and the cornea, and typically appears early in the illness (often within the first few days).

While the conjunctivitis itself is usually mild and does not cause pain or vision loss, it is an important diagnostic clue because, when combined with other KD criteria, it signals a disease that can lead to serious coronary artery complications if not treated promptly.

Common Causes

Conjunctival redness can occur in many conditions. In the context of Kawasaki disease, the conjunctivitis is a manifestation of systemic inflammation, but clinicians must consider other possibilities until KD is confirmed. Below are the most frequent causes of bilateral, non‑purulent conjunctivitis in children:

• Kawasaki disease – vasculitis with characteristic bilateral conjunctival injection.
• Viral conjunctivitis – adenovirus, enterovirus, or influenza viruses.
• Allergic (vernal) conjunctivitis – seasonal allergies, often with itching.
• Scarlet fever – caused by group A Streptococcus; associated with a “sandpaper” rash.
• Measles (rubeola) – Koplik spots plus conjunctivitis in the prodrome.
• Hand‑foot‑mouth disease – enterovirus infections that can cause mild conjunctival redness.
• Reactivation of herpes simplex virus – usually unilateral but can be bilateral.
• Systemic autoimmune diseases – e.g., juvenile idiopathic arthritis, Behçet’s disease.
• Drug reactions – sulfonamides or topical ophthalmic agents.
• Exposure to irritants – smoke, chlorine, or chemical splashes.

Associated Symptoms

Kawasaki disease is diagnosed when ≥ 5 of the principal clinical criteria are present, along with fever lasting ≥5 days. The conjunctivitis is rarely isolated; the following signs frequently accompany it:

• Prolonged fever (often >39 °C/102.2 °F) that does not respond to usual antipyretics.
• Oral mucosal changes – bright red “strawberry” tongue, fissured lips, or diffuse erythema of the oropharynx.
• Extremity changes – erythema and edema of the hands/feet, followed by desquamation (peeling) after 1–2 weeks.
• Polymorphous rash – non‑specific, often maculopapular, that can appear on trunk, extremities, or perineum.
• Cervical lymphadenopathy – usually a single, >1.5 cm node.
• Cardiac involvement – coronary artery aneurysms, myocarditis, or pericardial effusion (may be silent initially).
• Irritability or lethargy – especially in infants.
• Gastrointestinal symptoms – abdominal pain, vomiting, or diarrhea in up to 30 % of cases.

When to See a Doctor

Because untreated KD can cause permanent heart damage, timely medical evaluation is critical. Seek care promptly if a child has:

• Fever lasting ≥48 hours that does not improve with acetaminophen or ibuprofen.
• Redness of both eyes without discharge or pain, especially when paired with a rash or oral changes.
• Any combination of the classic KD features listed above.
• Persistent swelling or peeling of the hands/feet.
• New or worsening neck lymph node that feels hard or is larger than a pea.
• Signs of cardiac involvement (chest pain, rapid breathing, fainting) – these require immediate attention.

Even if the child appears otherwise well, err on the side of caution and contact a pediatrician or go to an urgent‑care clinic.

Diagnosis

There is no single laboratory test that confirms KD; the diagnosis is clinical, supported by laboratory and imaging studies.

1. Clinical criteria

According to the American Heart Association, the presence of fever ≥5 days plus ≥ 4 of the 5 principal features (conjunctival injection, oral changes, extremity changes, rash, cervical lymphadenopathy) establishes classic KD. Incomplete/atypical KD is diagnosed when fever and fewer than 4 features are present but additional laboratory or echocardiographic evidence suggests KD.

2. Laboratory evaluation

• Complete blood count – often shows elevated white blood cells with neutrophilia.
• Acute‑phase reactants – markedly increased C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
• Elevated liver enzymes, hypoalbuminemia, and sterile pyuria can be present.
• Serum electrolytes and renal function to monitor complications.

3. Cardiac imaging

Transthoracic echocardiography is the gold standard for detecting coronary artery dilation or aneurysms. Baseline echo should be performed at diagnosis, repeated at 2 weeks, 6–8 weeks, and later as indicated.

4. Additional tests (if needed)

• Chest X‑ray – to assess for cardiomegaly.
• Electrocardiogram (ECG) – for arrhythmias or ischemic changes.
• Viral panels – to rule out concurrent infections.

Treatment Options

Early treatment dramatically reduces the risk of coronary artery aneurysms—from ~25 % to <5 % when therapy is started within the first 10 days of illness.

1. Intravenous Immunoglobulin (IVIG)

Standard therapy is a single dose of IVIG 2 g/kg infused over 10–12 hours. The exact mechanism is unclear, but IVIG modulates immune activation and reduces vascular inflammation.

2. Aspirin

High‑dose aspirin (30–50 mg/kg/day divided every 6 hours) is given during the acute phase to lower fever and inflammation, then switched to low‑dose (3–5 mg/kg/day) antiplatelet therapy after the fever resolves, continuing for 6–8 weeks or longer if coronary abnormalities persist.

3. Rescue therapy for IVIG‑non‑responders

About 10–20 % of patients fail to become afebrile 36 hours after the initial IVIG dose. Options include:

• Second dose of IVIG.
• Corticosteroids (e.g., methylprednisolone 2 mg/kg/day).
• Infliximab (anti‑TNFα) or other biologics if refractory.

4. Supportive care

• Hydration – oral or IV fluids to prevent dehydration from fever.
• Antipyretics – acetaminophen for comfort (avoid NSAIDs until aspirin therapy is established).
• Eye care – artificial tears or lubricating ointment if ocular discomfort occurs.
• Skin care – gentle moisturizers; avoid harsh soaps that may aggravate rash.

5. Follow‑up

Children require regular cardiology follow‑up. Those with normal coronary arteries typically have echocardiograms at 2 weeks, 6–8 weeks, and a final study at 1 year. Persistent aneurysms may need lifelong surveillance, anticoagulation, and lifestyle counseling.

Prevention Tips

Because the exact trigger of Kawasaki disease remains unknown, primary prevention is limited. However, these measures can reduce the risk of secondary infections and support overall health:

• Practice good hand hygiene – wash hands with soap and water for at least 20 seconds.
• Avoid close contact with individuals who have active respiratory infections.
• Keep routine childhood vaccinations up to date (e.g., influenza, measles) to reduce viral illnesses that could mimic KD.
• Maintain a balanced diet rich in fruits, vegetables, and omega‑3 fatty acids to support a healthy immune system.
• Ensure adequate sleep; children need 10‑14 hours per night for optimal immunity.
• Educate caregivers about the early signs of KD so that treatment can start promptly.

Emergency Warning Signs

Key Take‑aways

• Kawasaki disease conjunctivitis is a bilateral, non‑purulent redness that is an early hallmark of a systemic vasculitis.
• It rarely occurs alone; look for fever, oral changes, rash, extremity swelling, and lymphadenopathy.
• Prompt diagnosis and treatment with IVIG + aspirin dramatically lower the risk of coronary artery aneurysms.
• Even if the eye symptoms are mild, the condition can be life‑threatening – seek pediatric care quickly.
• Follow‑up cardiac imaging is essential because coronary complications can develop weeks after the fever subsides.

References:

1. Mayo Clinic. Kawasaki disease. https://www.mayoclinic.org
2. American Heart Association. Diagnosis and Treatment of Kawasaki Disease. Circulation, 2022
3. Cleveland Clinic. Kawasaki disease in children. https://my.clevelandclinic.org
4. National Institutes of Health (NIH). Kawasaki Disease. https://www.nichd.nih.gov
5. World Health Organization. WHO classification of vasculitis. 2021